Marinus Pharmaceuticals Inc (STU:61Y)
€ 1.61 0.12 (8.05%) Market Cap: 88.85 Mil Enterprise Value: 82.45 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 36/100

Marinus Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 08:40PM GMT
Release Date Price: €10.5 (+1.70%)
Gautham Baliga
JP Morgan Chase & Co. - VP of Healthcare Investment Banking

Hello, everyone. Thank you for joining JPMorgan's Annual Healthcare Conference. I'm Gautham Baliga, Vice President in our Healthcare Investment Banking team. It's my pleasure to welcome Scott Braunstein, CEO of Marinus Pharmaceuticals to present on our platform. Please note that we'll go through some Q&A after Scott goes through the presentation, and you can ask the question by clicking on the Icon ask a question.

With that, I'll hand it over to Scott.

Scott Braunstein
Marinus Pharmaceuticals, Inc. - CEO, President & Director

Thanks, Gautham, and thanks for making the time this afternoon. I'll jump right into the presentation and leave plenty of time for Q&A.

Slide 2 of our investor deck is our safe harbor statement, and I'll let you review that on your own.

Slide 3 walks you through a little bit about ganaxolone. Ganaxolone is in is a GABA modulator that has a positive modulatory effects on the GABA receptor, both the synaptic and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot